Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

6 study records (showing up to 30 per record type)

• Registered trial NCT05864846 Phase 4 Not completed: Recruiting
  A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
  Condition or outcome area: Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
  2023-06-29 · Subject: Cannabidiol; abn-cbd, (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)olivetol; SCHEMBL16224872 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05324449 Phase 4 Not completed: Recruiting
  Epidiolex® for Anxiety in Pediatric Epilepsy
  Condition or outcome area: Anxiety|Epilepsy
  2022-04-05 · Subject: Cannabidiol; abn-cbd, (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)olivetol; SCHEMBL16224872 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05044819 Phase 4 Not completed: Active Not Recruiting
  Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
  Condition or outcome area: Lennox Gastaut Syndrome|Dravet Syndrome|Tuberous Sclerosis Complex
  2021-07-07 · Subject: Cannabidiol; abn-cbd, (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)olivetol; SCHEMBL16224872 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04899050 Phase 4 Completed (results not assessed here)
  Epidiolex in Typical Absence Seizures
  Condition or outcome area: Study the Efficacy of Epidiolex for Typical Absence Seizures
  2021-07-30 · Subject: Cannabidiol; abn-cbd, (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)olivetol; SCHEMBL16224872 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04447846 Phase 2 Completed (results not assessed here)
  Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome
  Condition or outcome area: Sturge-Weber Syndrome
  2019-10-14 · Subject: Cannabidiol; abn-cbd, (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)olivetol; SCHEMBL16224872 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT02397863 Not completed: Available
  Epidiolex and Drug Resistant Epilepsy in Children
  Condition or outcome area: Epilepsy
  2014-12 · Subject: Cannabidiol; abn-cbd, (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)olivetol; SCHEMBL16224872 · open the ingredient record · ClinicalTrials.gov